How big is the fusion biopsy market?

The market size of the fusion biopsy is estimated at USD 1.06 Billion in 2027.

What is the anticipated CAGR of the fusion biopsy industry?

Fusion Biopsy Market size was worth USD 974.51 Million in 2026 and is poised to grow at 10.49% CAGR between 2027 and 2036, attaining USD 2.64 Billion by 2036.

How is rising prostate cancer prevalence influencing adoption of fusion biopsy procedures?

Increasing demand for accurate diagnosis is encouraging healthcare providers to adopt fusion biopsy techniques that improve lesion localization, enhance tissue sampling precision, and support more informed clinical decision-making.

Why are imaging advancements accelerating growth in the fusion biopsy market?

Enhanced imaging systems, real-time image fusion, and improved software integration enable more precise biopsy targeting, streamline clinical workflows, and increase physician confidence in fusion-guided diagnostic procedures.

Why do fusion biopsy devices dominate the fusion biopsy market?

Fusion biopsy devices held an 83.1% market share in 2026 because they improve lesion localization and sampling accuracy, helping healthcare providers enhance diagnostic confidence and streamline image-guided biopsy workflows.

Why is the transperineal procedure the fastest-growing segment in the fusion biopsy market?

The transperineal procedure is growing fastest as healthcare providers increasingly adopt minimally invasive techniques that improve access to difficult-to-reach lesions while enhancing diagnostic accuracy and procedural precision.

Why is North America the leading fusion biopsy market?

North America accounted for 46.96% in 2026, supported by advanced healthcare infrastructure, image-guided diagnostic adoption, medical technology investment, and emphasis on precise cancer detection.

How is Asia Pacific accelerating fusion biopsy market growth?

Rising cancer awareness, expanding diagnostic capacity, improved hospital infrastructure, healthcare spending, and wider adoption of minimally invasive procedures are supporting regional growth.

Who are the major participants shaping the fusion biopsy landscape?

Leading players in the fusion biopsy market include GE HealthCare (USA), Siemens Healthineers AG (Germany), Koninklijke Philips N.V. (Netherlands), Canon Medical Systems Corporation (Japan), Esaote S.p.A. (Italy), Koelis SAS (France), Exact Imaging Inc. (Canada), CIVCO Medical Solutions (USA), Merit Medical Systems, Inc. (USA), Focal Healthcare Inc. (Canada)